Your browser doesn't support javascript.
loading
Non-psychotropic cannabinoids as inhibitors of TET1 protein.
Antonyová, Veronika; Kejík, Zdenek; Brogyanyi, Tereza; Kaplánek, Robert; Veselá, Katerina; Abramenko, Nikita; Ocelka, Tomás; Masarík, Michal; Matkowski, Adam; Gburek, Jakub; Abel, Renata; Goede, Andrean; Preissner, Robert; Novotný, Petr; Jakubek, Milan.
Afiliação
  • Antonyová V; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republi
  • Kejík Z; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republi
  • Brogyanyi T; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic.
  • Kaplánek R; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republi
  • Veselá K; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Te
  • Abramenko N; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic.
  • Ocelka T; CannabiLab, GMP Testing and Production Facility, E&H Services, Inc., Dobra 240, 73951, Czech Republic.
  • Masarík M; Department of Physiology and Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 8 CZ-625 00 Brno, Czech Republic.
  • Matkowski A; Department of Pharmaceutical Biology and Biotechnology, Wroclaw Medical University, Borowska 211, 50556 Wroclaw, Poland.
  • Gburek J; Department of Pharmaceutical Biochemistry, Wroclaw Medical University, Borowska 211A, 50556 Wroclaw, Poland.
  • Abel R; Department of Pharmaceutical Biology and Biotechnology, Wroclaw Medical University, Borowska 211, 50556 Wroclaw, Poland; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin
  • Goede A; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Philippstrasse 12, Berlin, Germany.
  • Preissner R; Science-IT and Institute of Physiology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Philippstrasse 12, 10115, Berlin, Germany.
  • Novotný P; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republi
  • Jakubek M; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republi
Bioorg Chem ; 124: 105793, 2022 07.
Article em En | MEDLINE | ID: mdl-35462234
ABSTRACT
Non-psychotropic cannabinoids (e.g., cannabidiol, cannabinol and cannabigerol) are contained in numerous alimentary and medicinal products. Therefore, predicting and studying their possible side effects, such as changes in DNA methylation, is an important task for assessing the safety of these products. Interference with TET enzymes by chelating ferrous ions can contribute to the altered methylation pattern. All tested cannabinoids displayed a strong affinity for Fe(II) ions. Cannabidiol and cannabinol exhibited potent inhibitory activities (IC50 = 4.8 and 6.27 µM, respectively) towards the TET1 protein, whereas cannabigerol had no effect on the enzyme activity. An in silico molecular docking study revealed marked binding potential within the catalytic cavity for CBD/CBN, but some affinity was also found for CBG, thus the total lack of activity remains unexplained. These results imply that cannabinoids could affect the activity of the TET1 protein not only due to their affinity for Fe(II) but also due to other types of interactions (e.g., hydrophobic interactions and hydrogen bonding).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canabidiol / Canabinoides / Cannabis Idioma: En Revista: Bioorg Chem Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canabidiol / Canabinoides / Cannabis Idioma: En Revista: Bioorg Chem Ano de publicação: 2022 Tipo de documento: Article